Introduction
Eorts in molecular and cellular biology over the past two decades have resulted in the discovery and development of breakthrough drugs that have started to ful®ll the promise of the biotechnology industry. In addition to products already on the market, large numbers of additional agents are in clinical trials, or awaiting approval. Moreover, with the revolution in genomic capabilities, the pace of target discovery has increased further which should lead to the discovery of many more therapeutically useful medicines with novel mechanisms of action.
Background

Cytokines and cytokine antagonists
Among the most successful biotechnology drugs that have reached the market are a variety of cytokines and cytokine modulators (see Table 1 ). The isolation and characterization of genes encoding cytokines and their receptors has greatly facilitated the analysis of cytokine function and application to disease. This has lead to the successful clinical application of several cytokines, such as the interferons, hematopoietic growth factors, and a variety of interleukins. The interferons provide signi®cant bene®t to patients suering from hepatitis B (Hoofnagle, 1990) or hepatitis C (Lindsay, 1999) , several cancers (Giralt et al., 1995; Spielberger and Golomb, 1992) , and multiple sclerosis (Panitch, 1995) .
The hematopoietic growth factors have also greatly changed patient treatment. Erythropoietin has almost completely removed the need for transfusion for patients with kidney failure (Eschbach et al., 1987) , and is also very useful in the treatment of other anemias (Stone et al., 1988) . Granulocyte-colony stimulating factor and granulocyte macrophage-colony stimulating factor are indicated for the treatment of neutropenia following chemotherapy (Welte et al., 1987 (Welte et al., , 1996 or bone marrow transplantation (Nemunaitis et al., 1998) . Both factors are also used to mobilize hematopoietic stem cells for collection and use in transplantation (Ahmed et al., 1992) .
Several antagonists of cytokine action have also been approved for clinical use. These include two products designed to antagonize TNFa action. One of these products utilizes a soluble form of the TNF receptor to block the interaction of TNF with its cellular receptor, while the other uses a neutralizing antibody that recognizes TNF to block receptor interaction. Blocking TNF action appears to have very signi®cant eects in controlling in¯ammatory events as evidenced by the clinical improvement seen with two in¯ammatory diseases, rheumatoid arthritis (Moreland et al., 1997) and Crohn's disease (Targan et al., 1997) . A similar approach has been used to modulate the activity of the human epidermal growth factor 2 (HER2) receptor. In this case a humanized antibody composed of human framework regions of an IgG1 kappa antibody with the appropriate complimentarity determining regions of a mouse monoclonal anti-HER2 antibody was generated that blocks activation of the HER2 receptor. This antibody is now used for treatment of patients with metastatic breast cancer whose tumors overexpress HER2 and who previously received one or more rounds of chemotherapy. It is also indicated in combination with paclitaxel for front-line therapy of metastatic breast cancer (Baselga et al., 1998) .
The growing number of drugs based on cytokines illustrates their value to medicine. Unfortunately, all of the medicines listed in Table 1 are recombinant proteins and as such they suer from a number of potential drawbacks. These can include diculty and expense of synthesis, a requirement for parenteral administration, and the potential for immune responses. The discovery of the intracellular signaling pathways activated by many of the above cytokines has made it possible to design screens to detect small molecule mimics and antagonists of the appropriate cytokines. It is particularly attractive to attempt to exploit the JAK/STAT signaling pathway for drug discovery, since this pathway is utilized by numerous cytokines and growth factors (Table 2) . Small nonpeptidyl cytokine modulators oer the potential of being easy to manufacture, orally bioavailable and non-immunogenic.
Cytokine signaling though JAKs and STATs
As shown in Figure 1 , cytokine signaling through the JAK/STAT pathway is initiated upon cytokine binding to its receptor causing receptor oligomerization. This is followed by a coordinated series of tyrosine phosphorylation events that lead to activation of a variety of signaling molecules, including the Signal Transducers and Activators of Transcription (STATs). The ®rst phosphorylation event is thought to involve crossphosphorylation of the Janus kinases (JAKs) associated with the receptor. The JAKs are a small family of tyrosine kinases that are associated with many cytokine or growth factor receptors. Phosphorylation of the JAKs leads to their activation and subsequent tyrosine phosphorylation of the receptor. The phosphorylated tyrosine residues provide docking sites for a variety of signaling molecules, including the STATs. The STATs are members of a family of transcription factors that currently include Stat1, Stat2, Stat3, Stat4, Stat5A, Stat5B and Stat6. Key domains of the STATs include an N-terminal interaction domain, a DNA binding domain, an SH2 domain, a conserved tyrosine phosphorylation site involved in SH2 interactions and a transcriptional activation domain. Once bound at the receptor, the STAT is phosphorylated by the receptor associated JAK kinase. Phosphorylation allows the STAT(s) to dimerize and enter the nucleus. The STAT dimer binds to speci®c DNA response elements within various promoters and activates transcription of downstream genes, leading to an altered cell phenotype. Ihle et al., 1994) . Asthma  GM-CSF  STAT5  JAK2  Myeloid reconstitution   IL-6  STAT1, STAT3  JAK1, JAK2, Tyk2  Inflamm., osteoporosis  IL-11  STAT3  JAK1, JAK2, Tyk2  Platelet production  LIF  STAT3  JAK1, JAK2, Tyk2  OSM  STAT1, STAT3  JAK1, JAK2, Tyk2  CNTF  STAT3  JAK1, JAK2, Tyk2  CNS  CT-1  STAT3  JAK1, JAK2, Tyk2  Cardiovascular  Leptin  STAT3, -1, -5  JAK2  Obesity   IL-12  STAT4, STAT3  Tyk2, JAK2  Immune regulation  G-CSF  STAT3, STAT5  JAK1, JAK2  Myeloid reconstituion  Epo  STAT5  JAK2  Anemia  Tpo  STAT5  JAK2  Platelet production  Prolactin  STAT5  JAK2  GH  STAT5, -3, -1  JAK2  GH insufficiency, aging   CSF-1/M-CSF  STAT1, STAT3  ?  EGF  STAT1, -3, -5  JAK1  Cancer  PDGF  STAT1, STAT3 ? Cancer Insulin STAT5, STAT1 ? Diabetes
As described below in the section on cell-based assays, activation of STATs provides a convenient readout that can be employed to detect small molecule modulators of cytokine action. In addition, the JAKs and STATs themselves, as well as proteins that regulate their activity, provide targets that can be screened in a directed fashion, as discussed in the section on biochemical assays.
Some of the cytokines that utilize the JAK/STAT pathway, such as EPO and interferon already have important medical uses (See Table 1 ). Other cytokines, like thrombopoietin, leptin, and IL-10 are currently undergoing clinical trials. As described in Table 2 , many of the cytokines involved in immune regulation oer attractive targets for control of diseases caused by an inappropriate or undesired immune response. This includes antagonists of IL-4, IL-9 and IL-13 for the treatment of allergy and asthma, and antagonists of IL-12 (or JAK3) for treatment of autoimmune diseases such as rheumatoid arthritis, and for control of transplant rejection. Finally, recent studies have demonstrated that activated STAT3 may have an important role in the development of a number of cancers (Bromberg et al., 1999) . Thus, antagonists of STAT3 could be very useful in the treatment of these cancers.
The availability of JAK and STAT reagents and the strong rationale for identifying small molecule modulators of cytokines has prompted the development and implementation of several JAK/STAT based screens. In some cases the activity of compounds detected in such screens have been described, and these data are reviewed below in the context of the speci®c assays used in their detection.
Cell-based assays
Assay formats Cytokines have numerous well-documented eects on responsive cell lines, most prominently regulation of proliferation and dierentiation. These are the long-term consequences of the activation of signal transduction pathways that occurs after binding of the cytokine to its receptor. High throughput screens for cytokine modulators can be con®gured that rely on proliferation or dierentiation of cell lines to provide a readout. However, assays of this type typically require several days to run, which reduces compound throughput and increases the number of compounds in the library whose activity may be masked by toxicity. As described above, activation of STATs is tightly linked to the binding of a cytokine to its receptor, and results in rapid changes in gene expression. This allows the con®gura-tion of cell-based assays for the detection of cytokine mimics or antagonists that can be run in a time frame of hours rather than days. As described below, assays which detect receptor dimerization directly allow even shorter run times, although they are limited to detecting compounds that act at a single target. Figure  2 compares some of the features of these dierent cellbased assay formats from the perspective of high throughput screening.
After activation, STATs acquire the ability to interact with speci®c DNA sequences known as STAT binding elements. Much work has been devoted to de®ning the DNA sequences that bind to each member of the STAT family, and this has revealed both commonalities and distinctions in the sequences bound Lamb et al., 1995; Decker et al., 1997) . When placed upstream of a minimal promoter, these elements mediate STATdependent transcription of linked reporter genes. Cells transfected with constructs of this type show large increases in reporter activity when treated with the appropriate cytokine, usually in a 2 ± 5 h time frame Lamb et al., 1995) . To con®gure a high throughput screen for cytokine modulators, a cell line responsive to the cytokine of interest is chosen, and transfected with a STAT-responsive reporter. If desired, the reporter can be selected such that its STAT binding elements are selectively bound by the STAT(s) activated by the test cytokine. Stable cell clones containing the reporter are isolated by drug selection, and a screening clone picked based on both the magnitude of reporter induction in response to cytokine, and on the absolute levels of reporter expression. To detect potential cytokine mimics, test compounds are incubated with the screening cell line in the absence of cytokine and compounds that cause an increase in reporter activity are selected for further study. An alternative con®guration is to run the assay in the presence of a low amount of cytokine (*EC 10 ). This allows the detection of compounds that may potentiate the activity of the cytokine, but which may not be able to activate signal transduction de novo. To detect cytokine antagonists, compounds are incubated together with the relevant cytokine and those which cause a decrease in reporter activity are selected for additional testing. A signi®cant proportion of the compound library (up to 10%, depending on the exact screening conditions chosen) will reduce reporter activity in a non-speci®c fashion, so it is important to have available a high throughput counterscreen that allows rapid elimination of such compounds. A constitutively active reporter transfected into the same cell background as used for the primary screen can serve as such a screen. Compounds that reduce reporter activity in this cell line are discarded. In general there are far fewer compounds that cause nonspeci®c increases in reporter activity (although they do exist), so it is not necessary to have a dedicated counterscreen when running screens for mimics.
In addition to being relatively rapid, screens of this type survey a number of potential targets simultaneously, rather than being focused on a single target. For example, in the case of an antagonist screen, compounds that act to block any one of a number of processes will be detected. These include; cytokine binding to receptor, receptor dimerization, JAK activity, JAK binding to receptor, STAT binding to receptor, STAT dimerization, STAT-DNA binding and STAT transcriptional activation. These transcriptionbased assays also have the advantage of surveying targets that are not yet de®ned or understood. This potentially increases the hit rate, but also means that the mechanism of action of a positive compound is not immediately apparent. However, it is usually possible to determine the mechanism of action of a lead compound found in such screens through subsequent experiments, as illustrated below. Figure 2 Comparison of three cell-based assay formats for detecting cytokine modulators. A schematic of each assay type is shown at the top. For the transcription assay, the circles inside the cell represent JAKs, whereas the rectangles are STATs. Two formats are shown for a receptor dimerization assay. In the top format, a FRET assay is illustrated (Damjanovich et al., 1997; Broudy et al., 1998) , using antibodies against the receptor conjugated to dierent¯uorescent tags, depicted by the dierent colored ellipses. In the lower format, a DHFR complementation assay is shown (Remy et al., 1999) , the DHFR fragments being represented by the ellipses attached to the cytoplasmic domain of the receptor, and the¯uorescent DHFR binding substrate shown as a square Alternative cell-based assay formats have been reported with the potential for even shorter run times and higher throughput than the reporter assays discussed above. For example, a method for immunoblotting cell lysates in high throughput has been described, which would allow direct detection of tyrosine phosphorylated JAKs or STATs (Stockwell et al., 1999) . This would reduce the compound incubation time to a matter of minutes rather than hours. Another approach relies on the ability to detect the dimerization or clustering of cytokine receptor chains that is induced by cytokine binding. At least two formats for such an assay have been described. In one,¯uorescence resonance energy transfer (FRET) is measured between appropriate labels attached to monoclonal antibodies against the receptor extracellular domain (Damjanovich et al., 1997; Broudy et al., 1998) . Alternately, a complementation assay based on fragments of the enzyme dihydrofolate reductase (DHFR) has been used to monitor receptor dimerization (Remy et al., 1999) . In this assay, chimeric receptor chains are constructed in which complementing fragments of DHFR are fused to the cytoplasmic domain of the receptor under study. Individually, neither of the DHFR fragments is capable of binding to methotrexate (MTX), but when the two fragments associate, they can bind to MTX and prevent it from being pumped out of the cell. Thus in cells expressing the receptor/DHFR chimeras, no MTX is retained in cells in the absence of cytokine, but when receptor clustering is induced by cytokine the DHFR fragments can associate and the substrate is retained. By usinḡ uorescein-conjugated MTX, the aggregation state of the receptor can be readily monitored, and compounds that either induce or inhibit aggregation detected.
Although these assays have the potential of being very high throughput, they are limited to detecting those compounds that act at the receptor. Compounds that act at potential intracellular targets, such as JAKs, STATs and negative regulatory proteins would not be detected by these screens.
Discovery of a small molecule cytokine mimic using a STAT-based screen Figure 3 shows an example of a STAT-based screen designed to detect mimics of G-CSF. A murine myeloid cell line expressing the G-CSF receptor was transfected with a STAT-responsive reporter, and a stable clone isolated that gave about a 20-fold induction of luciferase activity upon G-CSF treatment. Validation experiments run in high throughput format showed that this assay has a stable baseline and can detect compounds with ecacies as low as 10% that of G-CSF. This cell line was used to screen *110 000 individual compounds, and a single compound that triggered an increase in luciferase activity was studied further (Tian et al., 1998) . This compound, termed SB 247464, has a molecular weight of 526 and is symmetrical in structure (Figure 4 ). Its peak ecacy in the luciferase assay is about 30% of G-CSF activity at a concentration of 1 mM, and it exhibits a biphasic dose response curve (Figure 5a ). The potency of SB 247464 is many orders of magnitude lower than that of G-CSF. However, there is no requirement for a small molecule cytokine mimic to be equipotent with the natural ligand. Compound potency needs to be sucient to allow an acceptable dosing regime with a satisfactory therapeutic window in the treatment setting envisaged. A lower limit on potency is likely to be imposed by the requirement that a compound have a low enough o rate to allow receptors to be activated for long enough to promote eective intracellular signaling. The bell-shaped dose response curve is seen with several assays using the compound and is probably related to mechanism of action rather Figure 3 A high-throughput cell-based transcriptional assay con®gured to detect G-CSF mimics. A murine myeloid cell line was transfected with a STAT-responsive luciferase reporter and a stable clone isolated for use in screening. The left hand panel shows a dose response with respect to G-CSF using this cell line. The middle panel shows a mock screening plate, in which the output from cells treated with 0.3% DMSO in each of the wells of a 96 well plate is shown. Four of the wells in column 12 contain 10 ng/ml G-CSF. The right hand panel shows a mock screening plate con®gured to detect G-CSF potentiators. Cells were treated with 0.3% DMSO and an EC 10 of G-CSF. Four of the wells in column 12 contain 10 ng/ml G-CSF. The well-to-well variation in each of these formats is low, enabling sensitive detection of G-CSF mimics or potentiators than to toxic eects of the compound at high concentrations, as discussed below.
SB 247464 activates signal transduction pathways including JAKs and STATs ( Figure 5b ) consistent with its action as a G-CSF mimic. Activation of STATs by SB 247464 exhibits the characteristic bell shaped dose response curve discussed earlier. SB 247464 also supports the growth of G-CSF responsive cells, and promotes dierentiation of primary murine bone marrow cells into granulocytes (Figure 6a ). In this assay, the ecacy of the compound is close to that of G-CSF itself. Finally, injection of the compound into normal mice results in increases in peripheral blood neutrophil counts, which at a compound dose of 30 mg/kg are equivalent to the increases seen with a saturating amount of G-CSF (Figure 6b ). Eects on other hematopoietic lineages are not seen. The selectivity seen in vivo and is also observed in cell based assays performed in vitro. SB 247464 has not shown activity in assays that respond to cytokines other than G-CSF. In fact, this lead compound is selectively active in cells expressing murine G-CSF receptor, and has not shown detectable activity to date in assays measuring responses to the human G-CSF receptor.
To investigate the mechanism of action of the compound, we ®rst tested the role of the G-CSF receptor. Transfection of a construct directing the expression of murine G-CSF receptor into cells that do not express the receptor renders the cells responsive to SB 247464, suggesting that the compound acts at the receptor. Additional experiments demonstrate that the extracellular domain of the receptor is the target for SB 247464, however, the compound does not compete with G-CSF for binding to receptor, indicating that their binding sites are not the same. The murine and human G-CSF receptors share 67% amino acid identity; one or more of the amino acid changes is presumably responsible for the murine selectivity of SB 247464, even though both receptors respond to either human or mouse G-CSF.
The precise mechanism by which SB 247464 triggers activation of the G-CSF receptor is not known, but the data are consistent with a model in which the compound binds to two receptor chains, forming active receptor dimers. The symmetrical nature of SB 247464 makes this model attractive, providing as it does a ready explanation for the bell-shaped dose response curve evident in many of the assays. At high SB 247464 concentrations, all of the receptors on the cell surface will be bound to one molecule of SB 247464, leaving no unbound receptors free to form an active 2 : 1 complex with SB 247464. This is similar to the selfinhibition at high concentrations seen with several cytokines that bind to homodimeric receptors at two sites, including EPO and growth hormone (Schneider et al., 1997; Fuh et al., 1992 ). An interesting discussion of this eect and its implications has been presented elsewhere (Whitty and Borysenko, 1999) .
Regardless of the mechanism of action of SB 247464, the discovery of this compound illustrates that small non-peptidyl molecules can selectively activate cytokine receptors with enough ecacy to be useful. It also demonstrates that STATs, in addition to being potential drug targets in their own right, serve as useful markers of cytokine activity and can be used to detect small molecule modulators of cytokine receptor function. The successful use of cell-based assays to identify modulators of cytokine action has been detailed above. A second approach to ®nding small molecule modulators of cytokine signaling would be the use of biochemically based assays that directly target proteins involved in modulating signaling via the JAK/STAT pathway. Biochemical assays have several features that distinguish them from cell-based assays. First, biochemical assays are more targeted in that, by their very nature, the assays typically address only a single mechanism of action (although, as discussed below, more sophisticated assays can sometimes be con®gured to address more than a single mechanism). Attractive features of biochemical assays are: (i) they are higher throughput than cell-based assays, (ii) they will detect compounds that cannot cross an intact cell membrane, (iii) they can tolerate higher compound concentrations than cell-based assays and (iv) active compounds with cellular toxicity unrelated to their desired activity can be detected, allowing for separation of activity and toxicity at a later stage through appropriate medicinal chemistry optimization eorts. For these reasons, biochemical assays provide a useful complement to cell-based assays to discover modulators of cytokine action. The term biochemical assay' embraces a variety of assay formats; however, only a sampling of the possible biochemical assay con®gurations will be described below.
Inhibitors of enzymatic activity
The primary enzymes involved in cytokine signaling via the JAK/STAT pathway fall into two opposing categories, tyrosine kinases and tyrosine phosphatases. The ®rst ampli®cation step in signaling is the activation of JAK tyrosine kinase activity that occurs following cytokine-induced receptor clustering and conformational changes (Figure 1) . Indeed, the JAKs have been shown to be critical for virtually all subsequent signaling downstream of JAK-coupled cytokine receptors (Ihle, 1995) . Therefore, to block cytokine signaling, the JAKs would be an attractive target for an antagonist in therapeutic settings where inappropriate or excessive cytokine signaling occurs. There is clear precedent for the discovery and development of enzyme inhibitors in the pharmaceutical industry. Indeed, using classical assays for inhibitors of kinase catalytic activity (Racker, 1991) , selective inhibitors of tyrosine kinases can be identi®ed (Fry et al., 1994) . This concept has since been extended to the JAK family of tyrosine kinases. Using a known tyrosine kinase inhibitor pharmacophore as a starting point and a homology model derived from known kinase crystal structures, one research group has been able to design the compound WHI-P131 (Figure 4) , a JAK3-speci®c inhibitor with an IC 50 of 78 mM (Goodman et al., 1998; Sudbeck et al., 1999) . WHI-P131 shows at least ®vefold speci®city for Jak3 relative to Jak1, Jak2 and a number of other tyrosine kinases outside the JAK family. In addition to inhibition of Jak3 catalytic activity, WHI-P131 inhibits the growth of a number of Jak3-positive cell lines in vitro. Due to the role of Jak3 in lymphoid development and function, a Jak3 inhibitor could have utility in a variety of therapeutic settings including cancers such as leukemia and lymphoma as well as disorders caused by an overactive immune system. Interestingly, it has been reported that WHI-P131 is active in slowing progression in an animal model of amyotrophic lateral sclerosis (Trieu et al., 2000) . There has also been a report of a JAK2-speci®c inhibitor related to the tyrphostin class of compounds (Meydan et al., 1996) ; however, the actual activity/speci®city of this compound is unclear (Wang et al., 1999) .
In addition to the JAKs, which initiate signaling by biochemically activating signaling proteins through phosphorylation, tyrosine phosphatases likely play an opposite role to the kinases by removing phospho groups and thus dampening or shutting o signaling. To date, convincing data have been generated that support the notion that tyrosine phosphatases indeed are responsible for limiting the duration of response to cytokine (Haspel and Darnell, 1999) ; however, the identity of the speci®c phosphatase(s) has remained elusive. One exception is the case of erythropoietin (Epo) signaling. In the Epo system, there is good evidence that the SH2-domain containing phosphatase SHP-1 (HCP) negatively regulates Epo signaling (Klingmuller et al., 1995) . For example, a truncation of the intracellular domain of the Epo receptor that removes the recruitment site for SHP-1 results in a hyperactive receptor both in vitro and in vivo. Thus, inhibiting the catalytic activity of SHP-1 is a potentially interesting way of generating Epo-mimicking activity . The drawback of this approach, however, is the fact that SHP-1 also plays a role in the signaling of other receptors, which would render an inhibitor of SHP-1 catalytic activity pleiotropic in its pharmacological eects (Tsui et al., 1993) .
Although our current understanding, in terms of enzymes, places only tyrosine kinases and phosphatases at the center of JAK/STAT signaling, the biochemistry of the signaling systems is clearly not entirely worked out. For example, an enzyme of the arginine methyltransferase family has been identi®ed in a yeast twohybrid assay to associate with the Type I interferon receptor (Abramovich et al., 1997) . Reducing levels of this methyltransferase through antisense oligonucleotides appeared to inhibit interferon signaling. Interestingly, proteins in the arginine methyltransferase family have been shown to play a role in transcription as part of coactivator complexes (Chen et al., 1999) . It remains to be determined what role, this enzyme might play in signaling; nevertheless, this case clearly indicates that as our understanding of these systems increases, additional classes of enzyme targets may surface as attractive targets.
Macromolecular (protein ± protein and protein ± DNA) interactions as targets for inhibitors
The JAK/STAT signaling pathway is characterized by macromolecular interactions (protein ± protein and protein ± DNA), some constitutive and some inducible. Most of these interactions are depicted in Figure 1 and include cytokine binding to the receptor, receptor aggregation and conformational change, binding of the JAKs to the cytoplasmic face of the receptor, STAT recruitment to the activated receptor, STAT dimerization, STAT binding to DNA, STAT dimer ± dimer interactions and the association of STATs with other transcription factors and transcriptional coactivators. Several of these interactions represent points of speci®city in the signaling cascade, making them potentially attractive sites to intervene pharmacologically. Indeed, each of these interactions can be targeted, in principle, with an appropriately con®gured biochemical assay. Macromolecular interactions have been commonly examined using radioligand binding (including scintillation proximity assays), radioimmunological assays and enzyme-linked immunoassays, but newer assay technologies such as¯uorescence polarization and uorescence resonance energy transfer oer some advantages and have become increasingly popular.
For the purposes of this review, biochemical assays con®gured to detect inhibitors of STAT function will be discussed in more detail. Seven STAT proteins have been identi®ed in mammals (Stat1, Stat2, Stat3, Stat4, Stat5A, Stat5B and Stat6). The STATs have been found to play a vital role in a variety of biological processes; however, in several cases, the function of a particular STAT is remarkably speci®c. As shown in Table 2 , the biology associated with a given STAT in several cases has provided a compelling therapeutic rationale for inhibiting their function. For example, Stat6, which is only activated by IL-4 and IL-13, appears to have an exquisitely speci®c role in the humoral immune response, particularly that associated with dierentiation of T cells toward the T H 2 lineage and IgE production by B cells (Kaplan et al., 1996a; Shimoda et al., 1996; Takeda et al., 1996) . Therefore, inhibitors of Stat6 function would likely have ecacy in allergy and asthma without broadly suppressing immune responses. Stat4, which is speci®cally activated by IL-12, plays a similarly speci®c role in the immune system and is involved in driving dierentiation of T-helper cells toward a T H 1 response (Kaplan et al., 1996b; Thierfelder et al., 1996) . Thus, inhibitors of Stat4 function would likely have therapeutic utility in diseases mediated by the cell-mediated immune response, for example rheumatoid arthritis and multiple sclerosis. IFNg, a cytokine produced by T H 1 cells, signals via Stat1. The critical role of Stat1 in IFNg signaling makes it a potentially interesting target for immunomodulation, though the role of Stat1 in tumor surveillance (Kaplan et al., 1998) and the antiviral response (Durbin et al., 1996; Meraz et al., 1996) may make this approach problematic. Recent data have identi®ed activated Stat3 (and, in some cases, Stat5) to be present in a variety of cancer-derived cell lines as well as in cells directly isolated from cancer patients (Catlett-Falcone et al., 1999) . Detailed information on the role of STATs in cancer is discussed in accompanying articles, but, to summarize, Stat3 has been shown to be capable of driving cellular growth or transformation, perhaps most dramatically demonstrated in studies using a designed, constitutively activated Stat3 construct. In those studies (Bromberg et al., 1999) , it was found that constitutively active Stat3 was sucient to drive anchorage-independent growth of murine NIH3T3 and rat 3Y1 cells. Indeed 3Y1 cells expressing the constitutively active Stat3 were able to generate tumors in nude mice. Thus, an increasing volume of data supports the idea that Stat3 is a potentially attractive cancer target. In addition to its potential role in growth or transformation, Stat5 is a potentially interesting target for immunomodulation by virtue of its role in T cell activation, as revealed by the Stat5A/5B double-knockout mice (Moriggl et al., 1999) .
Assays targeting STATs
STAT proteins contain an SH2 domain as well as a DNA binding domain, and these domains are responsible for perhaps the most important known biochemical functions of STATs. First, recruitment of STATs to activated receptor complexes is mediated by the SH2 domain, which recognizes speci®c tyrosinephosphorylated residues on the cytoplasmic face of the receptor (Greenlund et al., 1995) . The SH2 domain also plays an obligate role in STAT dimerization, which occurs via twin head-to-tail SH2 domainphosphotyrosine interactions (Shuai et al., 1994) . The STAT, once dimerized, acquires the ability to bind DNA, which is mediated by a domain located Nterminal of the SH2 domain (Horvath et al., 1995) . Given their critical roles in STAT function, the SH2 domain and the DNA binding domain are attractive drug discovery targets. Several biochemical assay con®gurations that can measure the ability of a test compound to block SH2 domain or DNA binding domain function will be discussed below.
Biochemical screening assay formats Many biochemical assays are carried out using a solid support to which assay components are attached, often via an antibody or a biotin ± streptavidin interaction. One example of such an assay is depicted in Figure 7a . A tyrosinephosphorylated peptide encoding a STAT recognition site can be chemically synthesized with a biotin tag, and the biotin-labeled peptide can then be added to streptavidin-coated plates. The high-anity streptavidin ± biotin interaction anchors the peptide to the assay plate. Monomeric STAT protein can then be added to the plate with or without test compound. After washing, the amount of STAT remaining bound to the plate can be assessed using an anti-STAT antibody coupled to a convenient enzyme or¯uorescent label. A comparison of the amount of STAT bound to the plate in the absence of test compound with that in the presence of test compound allows the ready detection of inhibitors of STAT binding. Such an assay can be run in 96-well, 384-well and higher density plates, enabling the extremely rapid screening of large compound libraries. An example of actual assay data from such an assay con®gured in 96-well plates is shown in Figure 7b . As shown in Figure 7b , Stat1 binding to a biotin-labeled, tyrosine-phosphorylated peptide is challenged with either the cognate non-biotin-labeled, phosphorylated peptide or a non-phosphorylated version. The binding of Stat1 to the plate is clearly phosphorylationdependent, as expected. Such an assay could be used as a high-throughput screen to identify inhibitors of Stat1 recruitment to the activated IFNg receptor or STAT dimerization.
One can readily imagine a number of potential permutations of this basic assay, including reversing the polarity of the assay by coating the plate with STAT protein (with or without the assistance of an anti-STAT antibody) and assessing the binding of a peptide to the immobilized STAT. The ability of compounds to block STAT binding to the peptide can then be measured conveniently if the peptide is labeled. To facilitate the measurement of the ability of compounds to block peptide binding, a variety of labels including radioactive isotope or a¯uorescent label can be either coupled covalently or indirectly (e.g., via biotin ± streptavidin) to the peptide. If the peptide has a radioactive tag, a`scintillation proximity assay' can be used, which eliminates the need for wash steps following addition of the peptide.
These assays can also be con®gured to measure STAT ± DNA binding as well. For example, a biotinlabeled, double-stranded oligonucleotide encoding a STAT ± DNA binding site can be synthesized. The biotin-labeled oligonucleotide can be added to streptavidin-coated plates and activated STAT dimers (which can be generated in large amounts in insect cells when a JAK is co-expressed with a STAT (Quelle et al., 1995) ) added. Detection of STAT bound to the plate can then be accomplished as described above.
Assays that require ®xing components on a solid substrate are typically straightforward to set up and rapid to run; however, they suer from the drawback of having a large number of wash steps that are required at each stage of the assay. Not only do the wash steps take time, but they require that the biochemical interaction of choice be relatively high anity such that it can survive the many washes. Although the use of scintillation proximity assays (SPA) obviates the need for some wash steps (Braunwaler et al., 1996) , such assays require radioactivity with its attendant handling and disposal issues.
Simplified`mix and read' homogeneous assays
To obviate the need for any wash steps, a homogenous assay is required. In addition to SPA assays,¯uores-cence-based assays using FRET (Stryer, 1978) or uorescence polarization (FP) have been the most common solution to this problem (Silverman et al., 1998; Sittampalam et al., 1997) . FRET is a process that occurs when a donor¯uorescent molecule has an emission wavelength that overlaps the absorption wavelength of an acceptor. When the donor is excited, a non-radiative direct energy transfer to the acceptor occurs, but only when the donor and acceptor are in very close physical proximity (up to 10 nm). Thus, this process lends itself well to measuring the binding of two species that are labeled with the appropriatē uorescent tags. Due to the nature of the process, no wash steps are required, and the assay can be run simply by adding the appropriate reagents together and measuring signal. An assay con®gured to detect STAT Figure 7 (a) Depiction of an enzyme-linked biochemical assay capable of detecting compounds that disrupt the interaction of a Stat1 with a peptide containing its tyrosine-phosphorylated recognition site from the IFNg receptor (Greenlund et al., 1995) . The biotin-labeled (`B') IFNg receptor peptide is added to a streptavidin-coated (SA) microtiter plate. Recombinant Stat1 protein is then added with or without test compound. The amount of Stat1 remaining bound to the peptide can then be measured using a Stat1-speci®c antibody linked to a marker enzyme (e.g., horseradish peroxidase, HRP). (b) Sample data from a 96-well plate assay showing that Stat1 binding to a tyrosinephosphorylated peptide from the IFNg receptor is phosphotyrosine-speci®c. The cognate non-biotin-labeled, tyrosine-phosphorylated peptide (P-Tyr) disrupts the interaction, while the non-phosphorylated (Tyr) version does not binding to DNA is diagrammed in Figure 8a . In this con®guration, a biotin-labeled oligonucleotide probe encoding a STAT recognition site is linked to the acceptor chromophore allophycocyanin (APC) coupled to streptavidin. Activated, dimerized STAT, which has been expressed with a His antigen tag at its N-terminus is then added to the mixture together with an antibody directed against the His antigen. The anti-His antibody has been covalently coupled to a donor¯uorescent dye (in this case a europium cryptate). When the STAT is bound to the oligonucleotide, the two¯uorescent markers are brought into close physical proximity, leading to FRET when the system is excited with light of the appropriate wavelength. This is shown in Figure  8b as signal on the y-axis. The STAT binding to DNA is sequence-speci®c as can be demonstrated by the inhibition of the FRET signal by a speci®c unlabeled oligonucleotide competitor (but not by an irrelevant oligonucleotide). Indeed, the assay shown in Figure 8a , since it is a DNA binding assay, is actually capable of detecting compounds that might inhibit STAT function by two distinct mechanisms. Since STAT DNA binding requires STAT dimerization, this assay will not only detect direct inhibitors of DNA binding but also inhibitors of STAT dimerization. Lanthanide cryptates such as the europium cryptate have the property that excitation does not lead to immediate`prompt' uorescence (on the order of nanoseconds). Instead, they undergo time-resolved¯uorescence with an emission lifetime on the order of milliseconds. Therefore, the¯uorescent properties of some test compounds, which are usually characterized by prompt uorescence, do not interfere with the assay. This type of FRET assay has also been termed TR-FRET (timeresolved¯uorescence resonance energy transfer) (Kolb et al., 1997) . The sensitivity of the assay is high and thus can be run in very small volumes (25 mL in the example shown), allowing assay miniaturization. In addition, the signal can be internally normalized by using the ratio of the FRET signal to that of the background donor¯uorescence emission signal, thereby making the assay much less sensitive to well-to-well variations in reagent amounts. Lastly, because the assay is homogeneous, no wash or separation steps are necessary.
Fluorescence polarization (FP) (Nasir and Jolley, 1999) can be used as the basis of another homogeneous assay format to measure the interaction of a small molecule with a large molecule. According to the theory of FP, when a molecule is excited by planepolarized light of an appropriate wavelength, it will, after an emission timeframe typically on the order of nanoseconds, tend to¯uoresce in the same plane as the incoming light. Since molecules are constantly tumbling (in this case, the relevant frame of reference is with respect to the plane of the incoming light), the emitted light will tend to become depolarized. The extent to which the emitted light is depolarized will depend on the rate of tumbling. Since small molecules tend to tumble more rapidly than large molecules, the binding of a small molecule to a large molecule can be measured, because the small molecule, upon binding, will take on the slower tumbling rate of the larger molecule. The FP signal, as with FRET, can be measured as a ratio (bound versus free), providing an internal normalization that reduces assay variability and sample interference. Indeed, FP has been employed to con®gure an assay capable of measuring the binding of Stat1 to a tyrosine-phosphorylated peptide corresponding to the Stat1 recruitment site on the IFNg receptor (Wu et al., 1997) . The peptide was labeled with a¯uorescent dye, and its binding to the much larger Stat1 protein could be measured using FP. Again, because the assay is homogeneous, no wash or separation steps are necessary. The chief drawback of FP is sensitivity, and it may not be appropriate for use in systems where quantities of assay components are limited or interaction anities are weak. Figure 8 (a) Depiction of a homogeneous FRET-based biochemical assay capable of detecting compounds that disrupt STAT-DNA binding or STAT dimerization. A biotin-labeled (`B') double-stranded oligonucleotide encoding a STAT binding site is combined with the streptavidin-labeled (SA)¯uorescence acceptor allophycocyanin (APC, Fluor2). Recombinant STAT that has been tagged at the N-terminus with a His tag is combined with an anti-His monoclonal antibody conjugated to thē uorescence donor europium cryptate (Fluor1). Incubation of the DNA with the STAT brings the¯uorescence labels into close proximity, allowing FRET to occur as measured at the emission wavelength of the acceptor¯uor (hv 2 ) when the donor¯uor is excited by light of the appropriate wavelength (hv 1 ). B) Sample data from a 384-well plate assay showing that the observed FRET is dependent on the sequence-speci®c interaction of STAT with DNA. When increasing amounts of a speci®c oligonucleotide competitor (m67) encoding a STAT-binding element (Wagner et al., 1990) are added, the FRET signal disappears, indicating competition. However, when a non-speci®c oligonucleotide competitor corresponding to the DNA recognition site of an unrelated transcription factor (DR1) is added, no competition is observed In summary, a variety of high-throughput biochemical assay formats can be con®gured to test for compounds that block either JAK enzymatic activity or many of the macromolecular interactions characteristic of the JAK/STAT signaling pathway. Such compounds can then be tested for selectivity and optimized into drug candidates. In addition, as the roles of more recently described protein families (such as the SOCS (Starr et al., 1997) and PIAS (Chung et al., 1997; Liu et al., 1998) protein families) that interact with the JAK/STAT pathway become clear, new biochemical interactions can be targeted using these approaches. These eorts will lead to the identi®cation of new orally active drugs that inhibit (or mimic) the action of cytokines.
Discussion
Cytokines and cytokine antagonists have an important and rapidly growing place in the treatment of a wide variety of diseases. The discovery of the signal transduction pathways utilized by these medically relevant cytokines has made it possible to design high throughput screens to identify small molecule mimics and antagonists of these cytokines. Indeed, as described above, a small molecule with the ability of mimic the full spectrum of activities exhibited by G-CSF has been identi®ed. This presages a new age of drug discovery where orally bioavailable compounds may be used to replace current cytokine therapies. Moreover, small molecule mimics and antagonists of many additional cytokines will be discovered to treat a host of important diseases including autoimmune dysfunction, cancer, and metabolic disease.
